Bioprofarma Bagó is pleased to present the launch of the product NILTARA® nilotinib, for its Hematology Line.

This new product has been approved by ANMAT for the treatment of:

• Adult and pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML), recently diagnosed, in chronic phase;
• Adult patients with Philadelphia chromosome-positive CML in chronic phase and accelerated phase, with resistance or intolerance to previous treatment, including imatinib;
• Pediatric patients with Philadelphia chromosome-positive CML, in chronic phase, with resistance or intolerance to previous treatment, including imatinib.

NILTARA® nilotinib is now available in the following presentations:

• 150 mg x 120 hard capsules;
• 200 mg x 120 hard capsules.

NILTARA® nilotinib is the company’s 4th product for the treatment of CML, along with CLINID®imatinib, DAPIBUS®dasatinib and BIOPONIB®ponatinib.

This new treatment alternative is designed to provide specialists with more options for the care of their patients.

Bioprofarma Bagó
Working in the present, thinking the future.